AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25546001 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 42
Study 25546001 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 42
Study 23630016 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 0
Study 23630016 — intervention group
Group type: COMPARATOR
Intervention: Famotidine 40 mg
Number of subjects: 0
Study 23630016 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole 20 mg
Number of subjects: 0
Study 21646583 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led asthma self-management program
Number of subjects: 112
Study 21646583 — intervention group
Group type: COMPARATOR
Intervention: Conventional adult-led asthma program
Number of subjects: 112
Study 19057407 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 16
Study 19057407 — intervention group
Group type: COMPARATOR
Intervention: REST (passive sitting for 3 minutes)
Number of subjects: 16
Study 16891338 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl-eicosapentanoic acid (ethyl-EPA) 2 g per day
Number of subjects: 14
Study 16891338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 15060235 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycled lighting (239 +/- 29 lux, 7:00 AM to 7:00 PM; <25 lux, 7:00 PM to 7:00 AM; duration: 25 days)
Number of subjects: 62
Study 15060235 — intervention group
Group type: COMPARATOR
Intervention: Continuous dim lighting (<25 lux; duration 24 days)
Number of subjects: 62
Study 15060235 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycled lighting
Number of subjects: 62
Study 15060235 — intervention group
Group type: COMPARATOR
Intervention: Continuous dim lighting
Number of subjects: 62
Study 11509461 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT) self-help programme; 6 months follow-up
Number of subjects: 229
Study 11509461 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 229
Study 9586828 — intervention group
Group type: EXPERIMENTAL
Intervention: Active medication (beta-carotene 15 mg, vitamin C 150 mg, vitamin E 75 mg, selenium 101 microg, calcium 1.6 g daily)
Number of subjects: 116
Study 9586828 — intervention group
Group type: EXPERIMENTAL
Intervention: Active medication
Number of subjects: 116
Study 9586828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 7922794 — intervention group
Group type: EXPERIMENTAL
Intervention: rectal salmon calcitonin (sCT), 100 IU daily (n = 25)
Number of subjects: 42
Study 7922794 — intervention group
Group type: EXPERIMENTAL
Intervention: nasal salmon calcitonin (sCT), 200 IU daily (n = 17)
Number of subjects: 42
Study 7922794 — intervention group
Group type: COMPARATOR
Intervention: Control group (18 age‐matched women who received no treatment)
Number of subjects: 42
Study 3044871 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefatrizine 75 mg/kg.day once daily for 8 days
Number of subjects: 30
Study 3044871 — intervention group
Group type: COMPARATOR
Intervention: Cefatrizine 75 mg/kg.day twice daily for 8 days
Number of subjects: 30
Study 29143388 — intervention group
Group type: EXPERIMENTAL
Intervention: No core material
Number of subjects: 60
Study 29143388 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam core
Number of subjects: 60
Study 29143388 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin core
Number of subjects: 60
Study 29143388 — intervention group
Group type: COMPARATOR
Intervention: Control group (unrestored)
Number of subjects: 60
Study 27523961 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum (egg white powder)
Number of subjects: 383
Study 27523961 — intervention group
Group type: COMPARATOR
Intervention: Placebo (rice powder)
Number of subjects: 383
Study 25904376 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir (ATV/r)
Number of subjects: 328
Study 25904376 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL)
Number of subjects: 328
Study 25904376 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir (DRV/r)
Number of subjects: 328
Study 25904376 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 328
Study 23829621 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with house dust mite (HDM) extracts
Number of subjects: 0
Study 23829621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21138505 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency (1 Hz) rTMS
Number of subjects: 12
Study 21138505 — intervention group
Group type: COMPARATOR
Intervention: Sham placebo
Number of subjects: 12
Study 19266214 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (E)
Number of subjects: 62
Study 19266214 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (S)
Number of subjects: 62
Study 19266214 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined strength and endurance training (SE)
Number of subjects: 62
Study 19266214 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 62
Study 16505512 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan
Number of subjects: 1063
Study 16505512 — intervention group
Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 1063
Study 15295345 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape
Number of subjects: 344
Study 15295345 — intervention group
Group type: COMPARATOR
Intervention: Colposuspension
Number of subjects: 344
Study 11399214 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily maintenance doses of 4 mg/70 kg (n = 14) or 8 mg/70 kg (n = 19) of liquid buprenorphine
Number of subjects: 33
Study 11399214 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple the daily maintenance dose every 72 hours (12 or 24 mg/70 kg)
Number of subjects: 33
Study 11399214 — intervention group
Group type: EXPERIMENTAL
Intervention: Quintuple the daily maintenance dose every 120 hours (20 or 40 mg/70 kg)
Number of subjects: 33
Study 11399214 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-dosing procedures with three dosing regimens
Number of subjects: 33
Study 9399274 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast self-examination facilitation shield
Number of subjects: 52
Study 9399274 — intervention group
Group type: COMPARATOR
Intervention: No breast self-examination facilitation shield (control)
Number of subjects: 52
Study 8381674 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 g/day of a 85% n-3 fatty acid concentrate
Number of subjects: 14
Study 8381674 — intervention group
Group type: COMPARATOR
Intervention: Control group (no n-3 fatty acids)
Number of subjects: 14
Study 3690030 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate (1.5 mg.kg-1, orally twice a day for 14 days)
Number of subjects: 13
Study 3690030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 3690030 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate
Number of subjects: 13
Study 30849287 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual therapy for 6 weeks
Number of subjects: 41
Study 30849287 — intervention group
Group type: COMPARATOR
Intervention: Group therapy for 6 weeks
Number of subjects: 41
Study 30849287 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual therapy
Number of subjects: 41
Study 30849287 — intervention group
Group type: COMPARATOR
Intervention: Group therapy
Number of subjects: 41
Study 31099218 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (abdominal acupuncture + periodic therapy of Chinese herbal medicine)
Number of subjects: 84
Study 31099218 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal acupuncture
Number of subjects: 84
Study 31099218 — intervention group
Group type: COMPARATOR
Intervention: Western medication (clomiphene citrate + human chorionic gonadotrophin)
Number of subjects: 84
Study 28893106 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-gauge biopsy needles (PC22)
Number of subjects: 103
Study 28893106 — intervention group
Group type: COMPARATOR
Intervention: 25-gauge biopsy needles (PC25)
Number of subjects: 103
Study 25444222 — intervention group
Group type: EXPERIMENTAL
Intervention: Community consultation and public disclosure (CC/PD) process using multimedia approach
Number of subjects: 643000
Study 25444222 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of the CC/PD process
Number of subjects: 643000
Study 25444222 — intervention group
Group type: EXPERIMENTAL
Intervention: Effectiveness of the CC/PD process
Number of subjects: 643000
Study 23577719 — intervention group
Group type: EXPERIMENTAL
Intervention: Boiled barley kernels (BK)
Number of subjects: 19
Study 23577719 — intervention group
Group type: COMPARATOR
Intervention: White wheat bread (WWB)
Number of subjects: 19
Study 22010914 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier ART (within 2 weeks after the initiation of treatment for tuberculosis)
Number of subjects: 809
Study 22010914 — intervention group
Group type: COMPARATOR
Intervention: Later ART (between 8 and 12 weeks after the initiation of treatment for tuberculosis)
Number of subjects: 809
Study 22010914 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier ART (for patients with CD4+ T-cell counts of less than 50 per cubic millimeter)
Number of subjects: 809
Study 22010914 — intervention group
Group type: COMPARATOR
Intervention: Later ART (for patients with CD4+ T-cell counts of less than 50 per cubic millimeter)
Number of subjects: 809
Study 22010914 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier ART
Number of subjects: 809
Study 22010914 — intervention group
Group type: COMPARATOR
Intervention: Later ART
Number of subjects: 809
Study 22010914 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 809
Study 19332440 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally sensitive, seven-minute video intervention
Number of subjects: 0
Study 19332440 — intervention group
Group type: COMPARATOR
Intervention: Educational pamphlet
Number of subjects: 0
Study 17317365 — intervention group
Group type: EXPERIMENTAL
Intervention: Left bundle branch block (BBB) at randomization
Number of subjects: 5477
Study 17317365 — intervention group
Group type: EXPERIMENTAL
Intervention: Right bundle branch block (BBB) at randomization
Number of subjects: 5477
Study 17317365 — intervention group
Group type: EXPERIMENTAL
Intervention: Left bundle branch block (BBB) during follow-up
Number of subjects: 5477
Study 17317365 — intervention group
Group type: EXPERIMENTAL
Intervention: Right bundle branch block (BBB) during follow-up
Number of subjects: 5477
Study 15080862 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous apomorphine injection
Number of subjects: 0
Study 15080862 — intervention group
Group type: COMPARATOR
Intervention: Placebo application
Number of subjects: 0
Study 12584692 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg via 15-minute infusion)
Number of subjects: 0
Study 12584692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9652613 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine
Number of subjects: 262
Study 9652613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study 9652613 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine (excluding participants with colds)
Number of subjects: 262
Study 9652613 — intervention group
Group type: COMPARATOR
Intervention: Placebo (excluding participants with colds)
Number of subjects: 262
Study 7645530 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg 3 times daily)
Number of subjects: 100
Study 7645530 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (40 mg 3 times daily)
Number of subjects: 100
Study 2111669 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Flecainide acetate (1.5 mg/kg over 5 minutes) - Group I
Number of subjects: 19
Study 2111669 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Flecainide acetate (2 mg/kg over 5 minutes) - Group II
Number of subjects: 19
Study 359778 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular oxycodone
Number of subjects: 0
Study 359778 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine
Number of subjects: 0
Study 359778 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular codeine
Number of subjects: 0
Study 31232275 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium (UMEC) 62.5 µg once-daily added to fluticasone furoate/vilanterol (FF/VI) 200/25 µg once-daily
Number of subjects: 17
Study 27885712 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose plus albumin (group A)
Number of subjects: 120
Study 27885712 — intervention group
Group type: COMPARATOR
Intervention: Lactulose alone (group B)
Number of subjects: 120
Study 25536197 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl chloride spray
Number of subjects: 45
Study 25536197 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 45
Study 23415571 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinoplasty
Number of subjects: 110
Study 23415571 — intervention group
Group type: COMPARATOR
Intervention: Control (Septoplasty)
Number of subjects: 110
Study 21684715 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of autologous tissue repair cells (TRCs)
Number of subjects: 86
Study 21684715 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 86
Study 18332170 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin sprinkle (475 mg for ages 6 months to 4 years, 775 mg for ages 5 to 12 years) QD for 7 days
Number of subjects: 579
Study 18332170 — intervention group
Group type: COMPARATOR
Intervention: Penicillin VK (10 mg/kg QID for 10 days, max 250 mg QID)
Number of subjects: 579
Study 16823726 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (25 mg, bid)
Number of subjects: 98
Study 16823726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 15013052 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (VPA)
Number of subjects: 0
Study 15013052 — intervention group
Group type: COMPARATOR
Intervention: Control (phenytoin)
Number of subjects: 0
Study 10994155 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimebutine tablets (100 mg)
Number of subjects: 24
Study 10994155 — intervention group
Group type: EXPERIMENTAL
Intervention: New tablet formulation (Eurogalena, 100 mg)
Number of subjects: 24
Study 9116532 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipated discharge order forms
Number of subjects: 103
Study 9116532 — intervention group
Group type: COMPARATOR
Intervention: No anticipated discharge order forms (Control)
Number of subjects: 103
Study 8466376 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling Teflon catheter for heparin administration
Number of subjects: 12
Study 8466376 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily subcutaneous injections of heparin
Number of subjects: 12
Study 3725999 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 34
Study 3725999 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 34
Study 29921651 — intervention group
Group type: EXPERIMENTAL
Intervention: AlloCSC‐01
Number of subjects: 49
Study 29921651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 27336413 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mA anodal tDCS for 10 min
Number of subjects: 20
Study 27336413 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mA anodal tDCS for 20 min
Number of subjects: 20
Study 27336413 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mA anodal tDCS for 10 min
Number of subjects: 20
Study 27336413 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mA anodal tDCS for 20 min
Number of subjects: 20
Study 27336413 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions of anodal tDCS
Number of subjects: 20
Study 24781223 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory training
Number of subjects: 0
Study 24781223 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG-BFB-therapy
Number of subjects: 0
Study 24781223 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 23803696 — intervention group
Group type: EXPERIMENTAL
Intervention: rs2838732 (ITGB2) T allele
Number of subjects: 1841
Study 23803696 — intervention group
Group type: EXPERIMENTAL
Intervention: rs2838732 (ITGB2) T allele among never smokers
Number of subjects: 1841
Study 23803696 — intervention group
Group type: EXPERIMENTAL
Intervention: rs2838732 (ITGB2) T allele among former smokers
Number of subjects: 1841
Study 23803696 — intervention group
Group type: COMPARATOR
Intervention: Current smokers
Number of subjects: 1841
Study 22032072 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 40
Study 22032072 — intervention group
Group type: COMPARATOR
Intervention: Control (saline solution)
Number of subjects: 40
Study 18454658 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP + DFDBA
Number of subjects: 60
Study 18454658 — intervention group
Group type: COMPARATOR
Intervention: DFDBA + saline
Number of subjects: 60
Study 16585078 — intervention group
Group type: EXPERIMENTAL
Intervention: Cylinder oxygen
Number of subjects: 78
Study 16585078 — intervention group
Group type: EXPERIMENTAL
Intervention: Cylinder air
Number of subjects: 78
Study 16585078 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 78
Study 14748998 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) plus cyclophosphamide (CPA) intermittent intravenous pulse therapy (Group A)
Number of subjects: 30
Study 14748998 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) plus prednisone and tripterygium wilfordii hook f (T(whf)) (Group B)
Number of subjects: 30
Study 14748998 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone (Group C)
Number of subjects: 30
Study 10744208 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection speed of 20 seconds (group A)
Number of subjects: 70
Study 10744208 — intervention group
Group type: COMPARATOR
Intervention: Injection speed of 60 seconds (group B)
Number of subjects: 70
Study 8938306 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative intervertebral disk enhancement
Number of subjects: 94
Study 8938306 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear enhancement within the intervertebral disk
Number of subjects: 94
Study 8938306 — intervention group
Group type: EXPERIMENTAL
Intervention: End‐plate enhancement
Number of subjects: 94
Study 8938306 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical symptoms association with disk enhancement
Number of subjects: 94
Study 1543382 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled frusemide
Number of subjects: 21
Study 1543382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 3304518 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5FU) with postoperative levamisole
Number of subjects: 141
Study 3304518 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5FU)
Number of subjects: 141
Study 3304518 — intervention group
Group type: COMPARATOR
Intervention: Supportive treatment only (Control)
Number of subjects: 141
Study 29697830 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin with or without rosiglitazone, metformin plus lifestyle
Number of subjects: 190
Study 29697830 — intervention group
Group type: EXPERIMENTAL
Intervention: Irregular menses group
Number of subjects: 190
Study 29697830 — intervention group
Group type: COMPARATOR
Intervention: Regular menses group
Number of subjects: 190
Study 26792390 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief communication intervention (prompts) to aid solicitation of additional concerns (ACs)
Number of subjects: 18
Study 24490648 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation
Number of subjects: 332
Study 24490648 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions formed
Number of subjects: 332
Study 24490648 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation with implementation intentions formed
Number of subjects: 332
Study 24490648 — intervention group
Group type: COMPARATOR
Intervention: Control (no self-affirmation)
Number of subjects: 332
Study 24490648 — intervention group
Group type: COMPARATOR
Intervention: Implementation intentions not formed
Number of subjects: 332
Study 22615787 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (bilateral BL2, GB14, TE 23, Ex1, ST1, GB20, LI4, LI11 and single GV23)
Number of subjects: 150
Study 22615787 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears (sodium carboxymethylcellulose)
Number of subjects: 150
Study 20839418 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical steroids (mometasone furoate) applied twice daily
Number of subjects: 45
Study 20839418 — intervention group
Group type: COMPARATOR
Intervention: Intralesional steroids (triamcinolone acetonide) injected at monthly intervals (1 to 2 mg/kg)
Number of subjects: 45
Study 20839418 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical steroids (mometasone furoate)
Number of subjects: 45
Study 20839418 — intervention group
Group type: COMPARATOR
Intervention: Intralesional steroids (triamcinolone acetonide)
Number of subjects: 45
Study 18257978 — intervention group
Group type: EXPERIMENTAL
Intervention: Indiplon 10 mg
Number of subjects: 2
Study 18257978 — intervention group
Group type: EXPERIMENTAL
Intervention: Indiplon 20 mg
Number of subjects: 2
Study 18257978 — intervention group
Group type: EXPERIMENTAL
Intervention: Indiplon 5 mg
Number of subjects: 2
Study 18257978 — intervention group
Group type: COMPARATOR
Intervention: Zopiclone 7.5 mg
Number of subjects: 2
Study 18257978 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem 10 mg
Number of subjects: 2
Study 18257978 — intervention group
Group type: COMPARATOR
Intervention: Zopiclone 3.75 mg
Number of subjects: 2
Study 16925111 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating proteins (ESPs)
Number of subjects: 0
Study 12962794 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Number of subjects: 65
Study 12962794 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) with Mycophenolate Mofetil (MMF)
Number of subjects: 65